Clinical Research Papers:
Poor survival is associated with the methylated degree of Zinc-finger protein 545 (ZNF545) DNA promoter in gastric cancer
Metrics: PDF 974 views | HTML 1054 views | ?
Jingyu Deng1, Han Liang1, Guoguang Ying2, Qiuping Dong2, Rupeng Zhang1, Jun Yu3, Daiming Fan4, Xishan Hao1
1Department of Gastroenterology, Tianjin Medical University Cancer Hospital, City Key Laboratory of Tianjin Cancer Center and National Clinical Research Center for Cancer, Tianjin, China
2Central laboratory, Tianjin Medical University Cancer Hospital, City Key Laboratory of Tianjin Cancer Center and National Clinical Research Center for Cancer, Tianjin, China
3Institute of Digestive Disease, Li Ka Shing Institute of Health Science, Chinese University of HongKong, Shatin, HongKong
4State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China
Han Liang, e-mail: firstname.lastname@example.org
Xishan Hao, e-mail: email@example.com
Keywords: stomach, neoplasm, zinc-finger protein, survival, methylation
Received: November 16, 2014 Accepted: December 11, 2014 Published: February 26, 2015
Zinc-finger protein 545 (ZNF545) was identified as a gastric tumour suppressor and potentially independent prognostic factor. At the present study, we found that lower expression of ZNF545 was specific in gastric cancer (GC) tissues, and the inconsistently methylated levels of ZNF545 promoter were identified in the gastric cancer tissues. In the methylation-specific PCR (MSP) analysis cohort, we found that GC patients with hypermethylated ZNF545 promoter exhibited significantly shorter median OS than those with unmethylated ZNF545 promoter and those with hypomethylated ZNF545 promoter. In the other cohort, we also demonstrated that GC patients with three or more methylated CpG sites in the ZNF545 promoter were significantly associated with poor survival by using the bisulphite gene sequencing (BGS). The methylated degrees of five CpG sites (−232, −214, −176, −144 and −116) could also provide distinct survival discrimination of patients with GC. These findings indicated that the methylated CpG sites of the ZNF545 promoter could be used for the clinical prediction of the prognosis of GC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.